Biomarkers in Drug formulation

Drug formulation also covers the surrogate end points in the use of biomarkers and patient selection or companion diagnostics and provides insights into clinical biomarker discovery and biomarker development or validation with regulatory implications. Biomarker use can improve pharmaceutical development efficiency by helping to select patients most appropriate for treatment using a given mechanism, optimize dose selection, and provide earlier confidence in accelerating or discontinuing compounds in clinical development.

Biomarker in Drug discovery

 

Biomarker in Drug Design

 

Dose selection in Biomarker

 

Biomarkers of Toxicity & Pharmacology

 

Biomarkers in dose selection

 

Evaluation of dose respons

 

    Related Conference of Biomarkers in Drug formulation

    March 27-28, 2024

    6th International Conference on Digital Health

    London, UK
    April 24-25, 2024

    35th European Heart and Heart Failure Congress

    Paris, France
    June 21-22, 2024

    52nd Global Nursing & Healthcare Conference

    Rome, Italy
    September 09-10, 2024

    3rd Global Summit on Physiology and Metabolism of Thyroid

    Paris, France
    September 18-19, 2024

    29th International Conference on Skincare and Cosmetology

    Amsterdam, Netherlands
    September 19-20, 2024

    20th Global Biomarkers and Clinical Research Summit

    Amsterdam, Netherlands
    September 24-25, 2024

    5th Global Summit on Public Health

    Paris, France

    Biomarkers in Drug formulation Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in